Auxilium’s Peyronie’s Strategy: Start With Few Urologists, Broad Patient Population
This article was originally published in The Pink Sheet Daily
Executive Summary
Xiaflex is first drug approved for Peyronie’s disease; initial marketing will focus on physicians that already provide invasive treatment.
You may also be interested in...
Endo Makes A Play For Auxilium, But QLT Deal Gets In The Way
The Irish company made its interest for Auxilium public, but the takeover target is not ready to break its previous merger agreement with Canadian drugmaker QLT.
Xiaflex Sales Still Slow, But Other Indications In The Works
Auxilium’s Xiaflex sales still languish, but its older testosterone product continues to drive growth for the company.
Auxilium's Xiaflex Clears FDA With REMS To Educate Doctors On Safe Injection Techniques
REMS does not restrict type of physician who can administer the collagenase enzyme, which will launch in March.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: